Compare Boeing Co (BA) vs Summit Therapeutics Inc (SMMT) Price & Performance

Boeing (BA) trades at $232.14, down 0.28% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company's fundamentals reflect a recovery, with 2025 revenue at $89.46B and net income of $2.24B, though valuation ratios like P/E of 83.9 remain elevated. News highlights Boeing's strategic sale of subsidiaries to Archer Aviation, aiming to streamline operations.

Outlook is cautiously optimistic with a consensus price target of $280.83, implying 21% upside. Key opportunities include production ramp-up and backlog growth, while risks involve high debt, volatile cash flows, and competitive pressures. Investors should monitor execution on profitability targets and macroeconomic impacts on aerospace demand.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.